bladder cancer

The Rehovot, Israel-based firm expects to soon receive marketing clearance from the US Food and Drug Administration for its methylation-based Bladder EpiCheck test.

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.

The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.

Startup Prophet Genomics plans to commercialize the assay, dubbed Urine Exfoliated Cells Copy Number Aberration Detector, for early detection and monitoring of patients.